IMVT · Company research
Immunovant, Inc. Common Stock (IMVT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Understanding Momentum Shifts in (IMVT) - Stock Traders Daily | Understanding Momentum Shifts in (IMVT) Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 12, 2026 | neutral | 0 | 0.6 |
| How Investors May Respond To Immunovant (IMVT) After Sjögren’s Trial Failure - Simply Wall Street | How Investors May Respond To Immunovant (IMVT) After Sjögren’s Trial Failure Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class - Yahoo Finance | IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class - Stocktwits | IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Immunovant (IMVT) Slides Toward $31.62 as Shares Retreat Nearly 5% - PSAR Stop - https://www.siam.in/ | Immunovant (IMVT) Slides Toward $31.62 as Shares Retreat Nearly 5% - PSAR Stop https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 6, 2026 | neutral | 0 | 0.6 |
| Is Trial Failure Altering The Investment Case For Immunovant Stock (IMVT)? - Simply Wall Street | Is Trial Failure Altering The Investment Case For Immunovant Stock (IMVT)? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 2, 2026 | neutral | 0 | 0.6 |
| Immunovant (IMVT) Just Gave Investors Something To Think About - Yahoo Finance | Immunovant (IMVT) Just Gave Investors Something To Think About Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case - Yahoo Finance | Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case Yahoo Finance | View source ↗ | Yahoo Finance | Sep 27, 2026 | neutral | 0 | 0.6 |
| Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) - PR Newswire | Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) PR Newswire | View source ↗ | PR Newswire | Sep 25, 2026 | neutral | 0 | 0.6 |
| IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down - The Globe and Mail | IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down The Globe and Mail | View source ↗ | The Globe and Mail | Sep 24, 2026 | neutral | 0 | 0.6 |
| IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down - Yahoo Finance | IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows - Stocktwits | Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows Stocktwits | View source ↗ | Stocktwits | Sep 23, 2026 | neutral | 0 | 0.6 |
| Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint - Yahoo Finance | Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint Yahoo Finance | View source ↗ | Yahoo Finance | Sep 23, 2026 | neutral | 0 | 0.6 |
| Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed | IMVT Stock News - Quiver Quantitative | Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed | IMVT Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 22, 2026 | neutral | 0 | 0.6 |
| Immunovant CTO Jay Stout sells $137,924 in IMVT stock - Investing.com | Immunovant CTO Jay Stout sells $137,924 in IMVT stock Investing.com | View source ↗ | Investing.com | Jul 10, 2026 | neutral | 0 | 0.6 |
| IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data - TradingView | IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data TradingView | View source ↗ | TradingView | May 21, 2026 | neutral | 0 | 0.6 |
| Immunovant Stock Surges Despite Disappointing Earnings Miss - Immunovant (NASDAQ:IMVT) - Benzinga | Immunovant Stock Surges Despite Disappointing Earnings Miss - Immunovant (NASDAQ:IMVT) Benzinga | View source ↗ | Benzinga | May 20, 2026 | neutral | 0 | 0.6 |
| Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update | IMVT Stock News - Quiver Quantitative | Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update | IMVT Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | May 20, 2026 | neutral | 0 | 0.6 |
| Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha | Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) Seeking Alpha | View source ↗ | Seeking Alpha | Apr 20, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.